This inventor holds 2 USPTO granted patents. Top assignee: Toshin Chemical Co., Ltd.. Active years: 1979-1986.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1979-1986
Title: Kenichi Ishibashi: Innovator in Medicinal Chemistry
Introduction
Kenichi Ishibashi is a notable inventor based in Urawa, Japan. He has made significant contributions to the field of medicinal chemistry, particularly through his innovative methods for synthesizing important pharmaceutical compounds. With a total of 2 patents, Ishibashi's work has the potential to impact the treatment of various heart-related diseases.
Latest Patents
Ishibashi's latest patents include a method for the preparation of isosorbide-5-nitrate and a method for the preparation of derivatives of uracil. The first patent describes a novel and efficient method for synthesizing isosorbide-5-nitrate, a promising medicinal compound for several diseases related to heart disorders. This method involves the direct nitration of isosorbide using concentrated nitric acid in a specific reaction medium that includes an aromatic hydrocarbon solvent, such as benzene, along with conventional acetic acid and acetic anhydride. After neutralizing the reaction mixture and removing the dinitrate byproduct, the mixture is treated with an aqueous solution of sodium hydroxide to precipitate a sodium salt of isosorbide-5-nitrate in the form of a hydrate. This hydrate sodium salt is then decomposed with an acid to yield the desired isosorbide-5-nitrate in high yield.
The second patent presents a sophisticated method for preparing N.sub.1 -(2-tetrahydrofuryl)-5-substituted or -unsubstituted uracil, particularly N.sub.1 -(2-tetrahydrofuryl)-5-fluorouracil. This method involves the reaction of the corresponding 5-substituted uracil compound with 2,3-dihydrofuran in the presence of a chlorosilane compound, such as dimethyldichlorosilane, and a catalytic amount of an organic amine compound. The reaction proceeds rapidly without disadvantageous side reactions, resulting in the desired compound with high purity and yield.
Career Highlights
Kenichi Ishibashi is currently associated with Toshin Chemical Co., Ltd., where he continues to advance his research in medicinal chemistry. His innovative approaches have garnered attention in the scientific community, contributing to the development of new therapeutic agents.
Collaborations
Ishibashi
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile